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Abstract
Objective—To compare effectiveness of three surfactant preparations (beractant, calfactant, and
poractant alpha) in premature infants for preventing three outcomes: (1) air leak syndromes; (2)
death; and (3) bronchopulmonary dysplasia (BPD) or death (composite outcomes).
Study design—We conducted a comparative effectiveness study of premature infants admitted
to 322 neonatal intensive care units in the U.S. from 2005–2010 who were treated with beractant,
calfactant, or poractant alfa. We compared the incidence of air leak syndromes, death, and
bronchopulmonary dysplasia (BPD) or death, adjusting for gestational age, antenatal steroids,
discharge year, and small-for-gestational-age status.
Results—51,282 infants received surfactant; 40% received beractant, 30% calfactant, and 30%
poractant alfa. Median birth weight was 1435 g (interquartile range 966–2065); median gestational
age was 30 weeks (27–33). On adjusted analysis, we observed a similar risk of air leak syndromes
(calfactant vs. beractant odds ratio [OR]=1.17 [95% confidence interval: 0.95, 1.43]; calfactant vs.
poractant OR=1.23 [0.98, 1.56]; beractant vs. poractant OR=1.06 [0.87, 1.29]), death (calfactant
vs. beractant OR=1.14 [0.93, 1.39]; calfactant vs. poractant OR=0.98 [0.78, 1.23]; beractant vs.
poractant OR=0.86 [0.72, 1.04]), and BPD or death (calfactant vs. beractant OR=1.08 [0.93, 1.26];
calfactant vs. poractant OR=1.19 [1.00, 1.41]; beractant vs. poractant OR=1.10 [0.96, 1.27]).
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Conclusions—Beractant, calfactant, and poractant alfa demonstrated similar effectiveness in
prevention of air leak syndromes, death, and BPD or death in premature infants when adjusted for
site. Previously described differences in mortality between surfactants likely do not represent true
differences in effectiveness but may relate to site variation in outcomes.
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Respiratory distress syndrome (RDS) causes significant morbidity and mortality in
premature infants. Exogenous surfactant replacement therapy for the treatment of RDS in
premature infants decreases severe RDS, pulmonary air leak syndromes, and death.1 Three
animal-derived surfactants are commercially available in the United States—beractant
(Survanta®), calfactant (Infasurf®), and poractant alfa (Curosurf®). All three preparations
are approved by the Food and Drug Administration (FDA) for use in infants to treat RDS.
Over the last 10 years, the use of surfactant in the United States has changed little, from 16%
to 19% among infants admitted to a neonatal intensive care unit (NICU).2 However, the
relative use of specific surfactant preparations has changed significantly. The use of
beractant has decreased from 95% to 42% of all surfactant administrations, and the use of
calfactant and poractant alpha has increased from 5% to 27% and 0% to 29%, respectively.2
Understanding the comparative effectiveness of surfactant preparations is important for
reducing neonatal morbidity and mortality. However, randomized trials comparing the
efficacy of surfactant preparations have often demonstrated equivocal results or were
terminated early due to lack of enrollment.3–6 No completed prospective studies directly
comparing the efficacy of the three surfactants within the same trial exist. Due largely to
cost and recruitment issues, further study through a head-to-head randomized trial of
surfactant therapy is unlikely, thus retrospective comparative effectiveness analyses or meta-
analyses are justified to determine the differences, if any, between surfactant preparations.
A recent retrospective cohort study suggested that poractant alfa was associated with a
reduced risk for in-hospital mortality when compared with calfactant and beractant (though
comparison with beractant was not statistically significant).7 Other experts have argued that
this conclusion is problematic as it is based on a retrospective study of an administrative
data set that is not a part of a daily documentation system.8 In addition, a significant portion
of the sample was not included in final models for analysis. A meta-analysis examining
randomized trials of porcine versus bovine surfactants in RDS also suggests that infants
treated with poractant alfa have a decreased risk of death as compared with those treated
with beractant.9 The trials included in the meta-analysis, which date from 1995–2005,
represent a small number of patients and may not be representative of current clinical
practice or effectiveness. We compared the effectiveness of beractant, calfactant, and
poractant alfa for preventing three outcomes: (1) air leak syndromes; (2) death; and (3)
bronchopulmonary dysplasia (BPD) or death (composite outcome).
METHODS
We conducted a comparative effectiveness study using an administrative database of infants
discharged from 322 NICUs managed by the Pediatrix Medical Group from January 1, 2005,
to December 31, 2010. Clinicians who provide direct care to infants in these NICUs
generate data on a daily basis for the purposes of creating progress notes and medical
billing. Daily notes are stored in an electronic database along with administered medications
and diagnoses. From the daily notes, data are extracted, de-identified (in compliance with
the Health Insurance Portability and Accountability Act of 1996), and consolidated into the
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Pediatrix BabySteps Clinical Data Warehouse. This study was approved by the Duke
University Institutional Review Board and Western Institutional Review Board.
We included all inborn infants with a gestational age (GA) <37 completed weeks who were
cared for at a single NICU and received beractant, calfactant, or poractant alfa. We excluded
infants admitted to NICUs that administered surfactant to <50 infants over the study period,
as well as infants who received >1 surfactant preparation (Figure).
Air leak syndrome was defined as a diagnosis of pneumothorax or pulmonary interstitial
emphysema following the first exposure to surfactant. Infants <32 weeks GA were classified
as having BPD if they received supplemental oxygen or respiratory support (nasal canula,
continuous positive airway pressure, or mechanical ventilation) continuously from a
corrected GA of 36 0/7 weeks to 36 6/7 weeks (designated as the test period). Infants ≥32
weeks GA at birth were classified as having BPD if they received supplemental oxygen or
respiratory support (nasal canula, continuous positive airway pressure, or mechanical
ventilation) continuously from a postnatal age of 28–34 days. The receipt of continuous
respiratory support or supplemental oxygen was required to more clearly define infants with
BPD as compared with those with a transient need for oxygen. Infants on room air without
any respiratory support during the respective test period were classified as not having BPD.
Infants discharged on room air prior to the test period and not receiving respiratory support
on the day of discharge were classified as not having BPD. Those who died before the test
period were classified as not having BPD. The outcome of BPD was left as missing if the
infant was discharged prior to the test period while receiving supplemental oxygen or
respiratory support. The composite outcome of BPD or death was defined as the diagnosis of
BPD and or all-cause in-hospital mortality.
Statistical Analyses
We used summary statistics to describe subjects according to the surfactant administered.
We compared categorical and continuous variables across the three surfactant types using
the chi-square tests of association and non-parametric Kruskal-Wallis tests, respectively. To
account for the correlated structure of our data within NICUs, we fit unconditional logistic
regression models as well as mixed models with random and fixed effects for NICUs.
We compared outcomes between infants who received beractant, calfactant, or poractant
alfa. Using prior knowledge of potential confounders, we included GA, birth weight, small-
for-gestational-age (SGA) status, antenatal steroid exposure, sex, race, and discharge year.
We used a backward elimination method to determine if our a priori covariates should
remain in the model and compared models with the full model containing all covariates
using likelihood ratio tests with a significance cut point of <0.1. The final variables included
in the model were GA, antenatal steroid exposure, SGA status, and discharge year.
For each outcome, we used the Hausman specification test to evaluate the correlation
between a NICU-specific effect and the included covariates. Given that the Hausman test
rejected the null hypothesis (P<0.001) for each outcome modeled, we concluded that there
was correlation between unobserved NICU-specific effects and the variables included in our
models. As a result, we opted to use conditional fixed effects logistic regression models for
our primary analyses. Conditioning on NICU addressed the heterogeneity of baseline risk of
outcomes in each NICU and allowed us to best estimate the treatment effect. The results of
unconditional logistic regression and random effects models were also included to compare
with estimates from prior studies. Effect measure modification was evaluated by including
interaction terms with GA and surfactant and by conducting likelihood ratio tests using a
significance cut-point of <0.1. No interaction terms were found to be significant. All
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analyses were conducted using STATA statistical software version 12 (College Station, TX),
and a P-value <0.05 was considered statistically significant.
RESULTS
We identified 51,282 infants with a median birth weight of 1435 g (interquartile range
[IQR]: 966–2065) and a median gestational age of 30 weeks (27–33) (Table I). Overall, 40%
of infants (n=20,383) were treated with beractant, 30% (n=15,748) with calfactant, and 30%
(n=15,151) with poractant alfa. During this time period, the use of beractant and calfactant
decreased and the use of poractant alfa increased.
Infants treated with poractant alfa were more mature and larger (median GA 31 weeks [IQR:
28–34], birth weight 1590 g [1050–2220]) when compared with those treated with beractant
(GA 30 weeks [27–33], birth weight 1390 g [940–2020]) or calfactant (GA 30 weeks [27–
33], birth weight 1360 g [930–1960]). A higher proportion of infants treated with calfactant
were born to mothers who were treated with antenatal steroids (Table I).
Air leak occurred in 3450 infants (7% overall; 8% beractant, 7% calfactant, 5% poractant
alfa). Death occurred in 4576 infants (9% overall; 10% beractant, 9% calfactant, 7%
poractant alfa). A total of 12,164 infants (22% overall; 27% beractant, 25% calfactant, 20%
poractant alfa) had a diagnosis of BPD or death (composite) (Table II). Three percent of
infants (n=1514) were missing data for determining the outcome of BPD, and 3% (n=1506)
were missing data for the outcome of BPD or death.
Regression Models
Fixed Effects Models—For the outcome of air leak syndromes, we observed no
significant differences among the three surfactants (calfactant vs. beractant odds ratio [OR]
= 1.17 [95% confidence interval: 0.95, 1.43], calfactant vs. poractant OR=1.23 [0.98, 1.56],
and beractant vs. poractant OR=1.06 [0.87, 1.29]) using a fixed effects model (Table III).
For the outcome of death alone, the fixed effects model showed no significant differences
among the three surfactants (calfactant vs. beractant OR=1.14 [0.93, 1.39], calfactant vs.
poractant OR=0.98 [0.78, 1.23], beractant vs. poractant OR=0.86 [0.72, 1.04]).
For the combined outcome of BPD or death, the fixed effects model showed no significant
differences among the three surfactants (calfactant vs. beractant OR=1.08 [0.93, 1.26],
calfactant vs. poractant OR=1.19 [1.00, 1.41], and beractant vs. poractant OR=1.10 [0.96,
1.27]).
Simple Logistic Regression and Random Effects Models—For the outcome of air
leak syndromes and the composite outcome of BPD or death, there was a statistical
difference between poractant versus calfactant or beractant in the simple logistic regression
models (air leak syndromes: calfactant vs. poractant OR=1.25 [1.13, 1.40], and beractant vs.
poractant OR=1.47 [1.35, 1.61] for BPD or death: calfactant vs. poractant OR=1.04 [0.95,
1.13], and beractant vs. poractant OR=1.35 [1.26, 1.43]). However, for the outcome of death
no difference was noted between calfactant and poractant (calfactant vs. poractant OR=1.04
[0.95, 1.13]. The random effects models showed similar statistical results to the fixed effects
models with the exception of air leak syndromes (calfactant vs. poractant OR=1.23 [1.04,
1.44] and beractant vs. poractant OR=1.31 [1.13, 1.51]).
DISCUSSION
In this large cohort of infants, we found that beractant, calfactant, and poractant alfa had
similar relative effectiveness at preventing air leak syndromes, death, and BPD or death in
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premature infants. These results are important as they indicate that there may be no clear
advantage of one surfactant over another based on important outcome measures. Given our
sample size of approximately 15,000 infants treated with poractant and 15,000 infants
treated with beractant, we had 80% power to demonstrate a 1.4% absolute difference for the
combined outcome of BPD or death.
Air leak syndromes are associated with short- and long-term morbidities including
hypotension, hypoxia, and intraventricular hemorrhage. Surfactant administration decreases
air leak syndromes such as pneumothorax and pulmonary interstitial enphysema when
compared with placebo.5,8–12 In this study, we found three surfactant preparations to be
similar to each other in preventing air leak syndromes. Overall, the incidence of air leak has
decreased significantly in the last several decades, likely due to a number of factors
including non-invasive ventilation, improvements in the technology of mechanical
ventilation, and surfactant therapy.13–16 The incidence of pneumothorax among infants <30
weeks GA in this study was similar to the incidence across the Vermont Oxford Network
(0–8.6% from 2005–2010), supporting the assumption that these data are representative of
national estimates.17
BPD is the most common serious pulmonary outcome in premature infants and is inversely
proportional to GA and birth weight.18 The incidence of BPD has not decreased despite
advances in respiratory care, in part due to increased survival of the lowest GA infants who
are at highest risk of BPD.14 Because surfactant therapy decreases the severity of RDS, it
was believed that surfactant might also lower the incidence of BPD. In addition, it seemed
possible that differences in surfactant preparations, such as surfactant proteins, might affect
the incidence of BPD. However, previous studies have not demonstrated a significant
difference in the risk of BPD with surfactant use or between different surfactant
preparations.3,4,19 Likewise, we observed no differences in the incidence of BPD or death
among surfactant preparations.
Prior to the availability of surfactant, mortality was a common outcome for extremely
premature infants.20 During our study period, mortality decreased among all but the lowest
gestational ages, with infants born at <24 weeks gestation. This is consistent with 2010 data
from the Vermont Oxford Network, which showed that mortality among infants with birth
weights between 500 g and 1500 g was at 65% in those <23 weeks GA.17
Surfactant therapy was originally developed to decrease the severity of RDS in extremely
and moderately preterm infants. FDA labeling for all three surfactants is based on studies
that focused on infants <30 weeks GA and birth weights <1250 g or those with evidence of
significant RDS.5,19,21 However, nearly half of the infants in our cohort were either
moderate- (GA between 31 0/7 weeks and 33 6/7 weeks) or late-preterm infants (GA
between 34 0/7 weeks and 36 6/7 weeks). Consistent with reports from the few prior studies,
our results suggest that a substantial portion of surfactant is used off-label and that current
practices are not evidence-based. As the number of preterm deliveries continues to increase,
of which late-preterm infants comprise the largest fraction, the role of surfactant in this
population needs to be closely evaluated.
The comparative effectiveness of surfactants has become a controversial topic.8, 22–24 In the
study by Ramanathan et al, they conclude that “poractant alfa treatment for RDS was
associated with a significantly reduced likelihood of death when compared with calfactant
and a trend toward reduced mortality when compared with beractant.”7 However, “there
were 8276 patients who met the selection criteria, yet were excluded due to unreported,
missing, or invalid entries for one or more of the variables: sex, race, APR-DRG, gestational
age or birth weight; the exclusion of these left 14,173 patients for use in the revised
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regression models.”8 Our results, based on a larger and less selected data sample, do not
support the conclusions offered by Ramanathan et al.
Site variation has been clearly linked to unexplained differences in outcomes such as BPD
and death in other studies. For example, the risk of BPD ranged from 7% to 48% among the
Neonatal Research Network centers in a randomized controlled trial of benchmarking to
reduce BPD in infants <1250 g birth weight.25 This variation was not explained by
differences in birth weight, GA, race, frequency of prenatal steroid use, or incidence of
RDS. Therefore, models that do not adequately account for site variation may produce
estimates that are difficult to interpret.
Differences between estimates of effectiveness among surfactant preparations in prior
studies and this study may be partially attributable to definitions and statistical methods,
including use of different modeling strategies. Modeling, in general, is used to evaluate the
association between an outcome of interest, such as death, and a main predictor of interest,
such as surfactant preparation, while controlling for other covariates. In simple logistic
regression, observations are assumed to be independent from each other. In cases where
subjects are clustered by center, this assumption may not be valid. Center-level effects may
influence associations between the predictor of interest and outcome.26 Random or fixed
effects models measure change within a group—for example, an individual center—and are
often used to account for these center-specific effects. By measuring change within a center
across multiple infants, these models can control for a number of potential omitted variables
unique to each center. Random effects models assume that center-specific effects are
uncorrelated with the other independent variables of the model, and fixed effects do not
require this assumption be met. This is an advantage of fixed effects models in certain
circumstances, as they remove potential bias that could result from the correlation between
site-specific effects and the independent variables. In our study, we believe that certain site-
specific effects may have been correlated with the choice of surfactant, making a fixed
effects modeling strategy more appropriate. This assumption was supported by the results of
the Hausman test. We therefore chose the fixed effects model to provide a more
conservative estimate of the true association between surfactant and outcome. The results
from this more conservative modeling strategy were significantly different from those using
simple logistic regression, which likely overestimated the association between surfactant
type and outcomes. Our study is limited by lack of randomization, and we may not have
accounted for all known and unknown confounders.
In recent years, the need for comparative effectiveness research has been fueled by the
emergence of new pharmaceuticals in the marketplace, as well as a push for cost
containment in medication expenditures. However, an important purpose for comparative
effectiveness research is also to assist decision-making by clinicians and purchasers to
improve the delivery of care.27 Prior studies have demonstrated the efficacy and cost
effectiveness of surfactant as compared with placebo in the setting of randomized controlled
trials; however, few have considered the effectiveness of surfactant preparations compared
with one another. Surfactant is an effective therapy, and further studies that would compare
all three surfactant preparations to placebo are unethical. Thus, comparative effectiveness is
one of the few methods available to understand how these products are performing in
clinical practice.27
In summary, we found no significant differences in the outcomes of air leak syndromes,
death, and BPD or death between infants treated with beractant, calfactant, and poractant
alfa. Also, nearly half of infants treated with surfactant were moderate- or late-preterm
infants, representing a significant amount of off-label use of this medication. Previously
described differences in mortality between surfactants likely do not represent true
Trembath et al. Page 6













differences in effectiveness but are accounted for by unmeasured site variation in outcomes.
Therefore, the decision regarding which surfactant preparation to use should be based on
factors other than effectiveness.
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Flow diagram of study eligibility. Abbreviations: GA, gestational age; NICU, neonatal
intensive care unit.
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